Indira Poola, Ph.D

Founder and President

Dr. Poola has been a breast cancer scientist for the past 20 plus years. She has worked as a professor in Howard University Medical School before starting this company. She is the recipient of 25 grant awards from 7 funding agencies, including NCI-NIH, NSF, DOD, Susan G. Komen for Cure, American Registry of Pathology, and Ella O. Latham Trust totaling more than $8 Million dollars. She has served in over 25 committees of 10 funding agencies, including NIH, DoD, NSF, EPA, Komen for Cure, California Breast Cancer Research Program, Institute of Medicine, Italian Ministry of Health, The National Medical Research Counsel of Singapore, and Florida Department of Health.

Dr. Poola has performed ground breaking research to understand the biology of precancerous breast tumors with funding from the NCI and Susan G. Komen for the Cure. For the first time Dr. Poola showed that progression from pre-cancer to cancer involved significantly increased levels of several cancer markers and the activation of a number of pathways that are known to promote cancer progression. Dr. Poola also showed that increased levels of certain oncoproteins predicted the actual development of breast cancer. These findings were published in highly prestigious medical journals (Nature Medicine 2005, PMID:864312; Clinical Cancer Research 2006, PMID: 16899629 and Clinical Cancer Research 2008, PMID: 18281563).

At Silbiotech, Inc., Dr. Poola expanded on the published findings to develop a multimarker cancer risk test, BBDRisk Dx™, with SBIR grant funding from NCI- NIH and NSF. Through her entrepreneurial efforts Dr. Poola has successfully translated her basic science research ideas into a commercial clinical diagnostic test including the validation of novel biomarkers and development of a propriatory algorithm for risk stratification.

Selected Publications of Dr. Poola in Cancer Research:

- **Poola** , et al. (2005) Nature Medicine, 11, 481-483. PMID:864312

- **Poola** et al. (2006) Clinical Cancer Research 12, 4773-4783 PMID: 16899629.
- **Poola**, et al. (2008) Clinical Cancer Research, 14, 1274-1280. PMID: 18281563
- **Poola**, et. al (2005) Clinical Cancer Research , 11, 7579-7585.
- **Poola**, et. al (2005) Endocrine 27, 227-23.
- **Poola**, (2009) Cancer Treat. Res 147:1-6,
- **Poola**, et al (2009) FEBS LETTERS 583, 3069-3075.
- **Poola**, et al. (2008) Breast Cancer: Basic and Clinical Research, 1, 1-14.
- D. J. Scott, et al. **Poola** and others (2007). Int. J. Oncology 3, 557-65.
- **Poola** and Q. Yue (2007), BMC Cancer 7:56.
- S. Fu, A et al, **Poola** and others (2003) Breast Cancer Res. 504, 82-87
- **Poola** (2003) Analytical Biochemistry 314, 217-226.
- **Poola** (2003) Endocrine 22, 101-111.
- **Poola**, et al. (2002) J. Steroid Biochemistry and Molecular Biology. 82, 169-79.
- **Poola**, et al. (2002) FEBS LETTERS, 516, 133-138.
- **Poola** et al (2002) CANCER 94, 615-623.
- **Poola** & Speirs (2001) J. Steroid Bioche. and Mol. Biol. 78, 459-469.
- S. Koduri & **Poola** (2001) Steroids , 66, 17-23.
- Koduri, Fuqua & **Poola** (2000). J. Cancer Res. and Clinical Onco., 126, 291
- **Poola**, et al (2000) J. Steroid Biochem. and Mol. Biol. 72, 249-258.
- Williams, others & **Poola** (1999) Analytical Biochemistry 271, 194-197.
- **Poola**, et al. (1998) Analytical Biochemistry, 258, 209-215.
- **Poola**, et al (1998) Analytical Biochemistry, 258, 209-215.
- Huang, et al and **Poola** (1998) Cancer Res, A3651
- **Poola** & Kiang (1994) J. Biological Chemistry, 269, 21762-21769.
- **Poola**, et al (1990) Biochem. Bioiphys. Res. Comm. 26-32.
- **Poola** & Lucas (1988) J. Biological Chemistry.263, 19137-46.
- **Poola** (1997) FEBS LETTERS, 416, 139-142.
- **Poola**, & Graziano (1998) J. Exp. Clinical Cancer Res. 17, 1-8.
- Avedissian, **Poola** et al (1995) Biochem. Biophys. Res. Commun. 216, 62-68.
- **Poola** & Narasimhan (1988) Biochemical Journal 250, 117-124.